

ubstance identification.

=> s (BISPHOSPHONATE# OR ALENDRONATE OR ?DRONATE) (S) (EFFERVES?)

1015 BISPHOSPHONATE#

486 ALENDRONATE

882 ?DRONATE

5870 EFFERVES?

L1 25 (BISPHOSPHONATE# OR ALENDRONATE OR ?DRONATE) (S) (EFFERVES?)

=> s l1(s)encapsul?

116768 ENCAPSUL?

L2 0 L1(S) ENCAPSUL?

=> s (BISPHOSPHONATE# OR ALENDRONATE OR ?DRONATE) (S) ENCAPSUL?

1015 BISPHOSPHONATE#

486 ALENDRONATE

882 ?DRONATE

116768 ENCAPSUL?

L3 20 (BISPHOSPHONATE# OR ALENDRONATE OR ?DRONATE) (S) ENCAPSUL?

=> s l3 not py>=2001

747179 PY>=2001

L4 4 L3 NOT PY>=2001

=> d ibib 1-4

FILE 'EUROPATFULL' ENTERED AT 16:54:15 ON 12 JUN 2003
COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

FILE 'PATDPAFULL' ENTERED AT 16:54:15 ON 12 JUN 2003
COPYRIGHT (C) 2003 DPMA

FILE 'PCTFULL' ENTERED AT 16:54:15 ON 12 JUN 2003
COPYRIGHT (C) 2003 Univentio

FILE 'RDISCLOSURE' ENTERED AT 16:54:15 ON 12 JUN 2003
COPYRIGHT (C) 2003 Kenneth Mason Publications Ltd.

FILE 'USPATFULL' ENTERED AT 16:54:15 ON 12 JUN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:54:15 ON 12 JUN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 16:54:15 ON 12 JUN 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

=> e mccallister d/in

'IN' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'RDISCLOSURE'

E1	1	MCCALLISTER C W/IN
E2	1	MCCALLISTER CHARLES W/IN
E3	0 -->	MCCALLISTER D/IN
E4	1	MCCALLISTER DENNIS L/IN
E5	2	MCCALLISTER III MYRON R/IN
E6	1	MCCALLISTER J/IN
E7	1	MCCALLISTER JAMES J/IN
E8	5	MCCALLISTER JOHN/IN
E9	1	MCCALLISTER JOHN S/IN
E10	1	MCCALLISTER KENNETH R/IN
E11	1	MCCALLISTER MERLAN E/IN
E12	7	MCCALLISTER PATRICK E/IN

The indicated field code is not available for EXPAND in this file. To see a list of valid EXPAND field codes, enter HELP SFIELDS at an arrow prompt (=>).

=> e rosen c/in

'IN' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'RDISCLOSURE'

E1	8	ROSEN BRUNO/IN
E2	6	ROSEN BRUNO DR 5603 WUELFRATH DE/IN
E3	17 -->	ROSEN C/IN
E4	458	ROSEN C A/IN
E5	5	ROSEN C D/IN
E6	1	ROSEN C F/IN
E7	1	ROSEN C M/IN
E8	1	ROSEN C N/IN
E9	1	ROSEN C T/IN
E10	11	ROSEN C Z/IN
E11	1	ROSEN CARL DAVID/IN
E12	1	ROSEN CARL ERIK M/IN

The indicated field code is not available for EXPAND in this file. To see a list of valid EXPAND field codes, enter HELP SFIELDS at an arrow prompt (=>).

=> s e3-e10

'IN' IS NOT A VALID FIELD CODE

L1 496 ("ROSEN C"/IN OR "ROSEN C A"/IN OR "ROSEN C D"/IN OR "ROSEN C

=> d his

(FILE 'HOME' ENTERED AT 19:00:39 ON 12 JUN 2003)

FILE 'USPATFULL' ENTERED AT 19:01:00 ON 12 JUN 2003

L1 2 S (BISPHOSPHONATE# OR ALENDRONATE OR
?DRONATE) (S) MICROENCAPSUL?

FILE 'EUROPATFULL, PATDPAFULL, PCTFULL, RDISCLOSURE, USPATFULL, USPAT2,
WPIDS' ENTERED AT 19:03:20 ON 12 JUN 2003

L2 5 S L1

L3 3 S L2 NOT US

L9 ANSWER 7 OF 11 USPATFULL

ACCESSION NUMBER: 1999:155712 USPATFULL
TITLE: Method for inhibiting bone resorption
INVENTOR(S): Daifotis, Anastasia G., Westfield, NJ, United States
Santora, II, Arthur C., Watchung, NJ, United States
Yates, A. John, Westfield, NJ, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5994329		19991130
APPLICATION INFO.:	US 1998-134214		19980814 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1998-US14796, filed on 17 Jul 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-53535P	19970723 (60)
	US 1997-53351P	19970722 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Criares, Theodore J.	
LEGAL REPRESENTATIVE:	Sabatelli, Anthony D., Winokur, Melvin	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	1324	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD Generalized bone loss is often associated with **osteoporosis**. **Osteoporosis** is most common in post-menopausal women, wherein estrogen production has been greatly diminished. However, **osteoporosis** can also be steroid-induced and has been observed in males due to age. **Osteoporosis** can be induced by disease, e.g. rheumatoid arthritis, it can be induced by secondary causes, e.g., glucocorticoid therapy, or it can come about with no identifiable

cause, i.e. idiopathic **osteoporosis**. In the present invention, preferred methods include the treatment or prevention of abnormal **bone** resorption in osteoporotic humans.

DETD . . . methods and compositions of the present invention are useful for treating and or preventing the following conditions or disease states: **osteoporosis**, which can include post-menopausal **osteoporosis**, steroid-induced **osteoporosis**, male **osteoporosis**, disease-induced **osteoporosis**, idiopathic **osteoporosis**; Paget's disease; abnormally increased **bone** turnover; periodontal disease; localized **bone** loss associated with periprosthetic osteolysis; and **bone** fractures.

DETD Compositions useful in the present invention comprise a pharmaceutically effective amount of a **bisphosphonate**. The **bisphosphonate** is typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers, collectively referred to herein as "carrier materials", suitably selected with respect to oral administration, i.e. tablets, capsules, elixirs, syrups, **effervescent** compositions, powders, and the like, and consistent with conventional pharmaceutical practices. For example, for oral administration in the form of . . . cellulose, magnesium stearate,

mannitol, sorbitol, croscarmellose sodium and the like; for oral administration in liquid form, e.g., elixirs and syrups, **effervescent** compositions, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, . . . oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. A particularly preferred tablet formulation for **alendronate** monosodium trihydrate is that described in U.S. Pat. No. 5,358,941, to Bechard et al, issued Oct. 25, 1994, which is . . .

DETD . . . compounds are orally dosed, at the desired dosage, according to the dosing schedules of EXAMPLES 2-5, for treating or preventing **osteoporosis** or for treating or preventing other conditions associated with abnormal **bone** resorption.

L9 ANSWER 8 OF 11 USPATFULL

ACCESSION NUMBER: 1999:132798 USPATFULL
 TITLE: Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
 INVENTOR(S): Yates, Ashley J., Westfield, NJ, United States
 PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5972913		19991026
APPLICATION INFO.:	US 1998-82237		19980520 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-876898, filed on 16 Jun 1997, now patented, Pat. No. US 5891863 which is a continuation of Ser. No. US 1994-230670, filed on 21 Apr 1994, now patented, Pat. No. US 5646134, issued on 8 Jul 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Sabatelli, Anthony D., Winokur, Melvin		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	385		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . herein refers to a living vertebrate animal such as a mammal in

need of treatment, i.e., in need of periprosthetic **bone** repair. The periprosthetic **bone** loss may arise in cases of systemic **bone** disease, as in **osteoporosis** (of any etiology), osteoarthritis, Paget's disease, osteomalacia, multiple myeloma and other forms of c

=> d his

(FILE 'HOME' ENTERED AT 16:54:03 ON 12 JUN 2003)

FILE 'EUROPATFULL, PATDPAFULL, PCTFULL, RDISCLOSURE, USPATFULL, USPAT2, WPIDS' ENTERED AT 16:54:15 ON 12 JUN 2003

E MCCALLISTER D/IN

E ROSEN C/IN

L1	496 S E3-E10
L2	0 S L1 AND FL
L3	49 S (BISPHOSPHONATE# OR ALENDRONATE OR ?DRONATE) (S) (EFFERVES?)
L4	46 S L3 (L) (BONE OR OSTEOPOROSIS)
L5	44 S L4 AND METHOD#
L6	12 S L5 NOT PY>=2001
L7	26 S L5 NOT PY>=2002

FILE 'USPATFULL' ENTERED AT 17:43:39 ON 12 JUN 2003

L8	20 S L3 (L) (BONE(S) OSTEOPOROSIS)
L9	11 S L8 NOT PY>=2002

NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1425
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 26 USPATFULL

ACCESSION NUMBER: 1999:155712 USPATFULL
TITLE: Method for inhibiting bone resorption
INVENTOR(S): Daifotis, Anastasia G., Westfield, NJ, United States
Santora, II, Arthur C., Watchung, NJ, United States
Yates, A. John, Westfield, NJ, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5994329		19991130
APPLICATION INFO.:	US 1998-134214		19980814 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1998-US14796, filed on 17 Jul 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-53535P	19970723 (60)
	US 1997-53351P	19970722 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Criares, Theodore J.	
LEGAL REPRESENTATIVE:	Sabatelli, Anthony D., Winokur, Melvin	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	1324	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 22 OF 26 USPATFULL

ACCESSION NUMBER: 1999:132798 USPATFULL
TITLE: Alendronate therapy to prevent loosening of, or pain
associated with, orthopedic implant devices
INVENTOR(S): Yates, Ashley J., Westfield, NJ, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5972913		19991026
APPLICATION INFO.:	US 1998-82237		19980520 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-876898, filed on 16 Jun 1997, now patented, Pat. No. US 5891863 which is a continuation of Ser. No. US 1994-230670, filed on 21 Apr 1994, now patented, Pat. No. US 5646134, issued on 8 Jul 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Sabatelli, Anthony D., Winokur, Melvin		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	385		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 23 OF 26 USPATFULL

ACCESSION NUMBER: 1999:43608 USPATFULL
TITLE: Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
INVENTOR(S): Yates, Ashley J., Westfield, NJ, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5891863		19990406
APPLICATION INFO.:	US 1997-876898		19970616 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-230670, filed on 21 Apr 1994, now patented, Pat. No. US 5646134		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Sabatelli, Anthony D., Winokur, Melvin		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	376		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 24 OF 26 USPATFULL

ACCESSION NUMBER: 1998:162033 USPATFULL
TITLE: Effervescent alendronate formulation
INVENTOR(S): Katdare, Ashok V., Norristown, PA, United States
Kramer, Kenneth A., Green Lane, PA, United States
Gardner, Colin R., Blue Bell, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5853759		19981229
APPLICATION INFO.:	US 1997-848460		19970508 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-17881P	19960517 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Spear, James M.	
LEGAL REPRESENTATIVE:	Sabatelli, Anthony D., Giesser, Joanne M., Winokur, Melvin	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
LINE COUNT:	301	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 25 OF 26 USPATFULL

ACCESSION NUMBER: 97:70733 USPATFULL
TITLE: Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions
INVENTOR(S): Rocco, William, Reading, PA, United States
Laughlin, Sharon M., Phoenixville, PA, United States

PATENT ASSIGNEE(S): Sanofi Winthrop, Inc., New York, NY, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5656288		19970812
APPLICATION INFO.:	US 1995-488986		19950608 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Spear, James M.		
LEGAL REPRESENTATIVE:	Davis, William J., Balogh, Imre		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 13 Drawing Page(s)		
LINE COUNT:	501		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 26 OF 26 USPATFULL

ACCESSION NUMBER: 97:59192 USPATFULL

TITLE: Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices

INVENTOR(S): Yates, Ashley J., Westfield, NJ, United States

PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5646134		19970708
APPLICATION INFO.:	US 1994-230670		19940421 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Giesser, Joanne M., Winokur, Melvin		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	358		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

F"/IN OR "ROSEN C M"/IN OR "ROSEN C N"/IN OR "ROSEN C T"/IN OR
"ROSEN C Z"/IN)

=> s l1 and FL

L2 0 L1 AND FL

L7 ANSWER 19 OF 26 USPATFULL

ACCESSION NUMBER: 2001:63671 USPATFULL
TITLE: **Method** for inhibiting bone resorption
INVENTOR(S): Daifotis, Anastasia G., Westfield, NJ, United States
Santora, II, Arthur C., Watchung, NJ, United States
Yates, A. John, Westfield, NJ, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6225294	B1	20010501
APPLICATION INFO.:	US 1999-440577		19991115 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-134214, filed on 14 Aug 1998, now patented, Pat. No. US 5994329 Continuation of Ser. No. WO 1998-US14796, filed on 17 Jul 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-53535P	19970723 (60)
	US 1997-53351P	19970722 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Criares, Theodore J.	
LEGAL REPRESENTATIVE:	Sabatelli, Anthony D., Winokur, Melvin	
NUMBER OF CLAIMS:	94	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	1470	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L7 ANSWER 20 OF 26 USPATFULL

ACCESSION NUMBER: 2000:7302 USPATFULL
TITLE: **Method** for inhibiting bone resorption
INVENTOR(S): Daifotis, Anastasia G., Westfield, NJ, United States
Yates, A. John, Westfield, NJ, United States
Santora, II, Arthur C., Watchung, NJ, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6015801		20000118
APPLICATION INFO.:	US 1998-134215		19980814 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1998-US14796, filed on 17 Jul 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-53535P	19970723 (60)
	US 1997-53351P	19970722 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Criares, Theodore J.	
LEGAL REPRESENTATIVE:	Sabatelli, Anthony D., Winokur, Melvin	
NUMBER OF CLAIMS:	59	
EXEMPLARY CLAIM:	1	